MIRECULE
MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
MIRECULE
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2016-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.mirecule.com
Total Employee:
1+
Status:
Active
Total Funding:
7.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Mobile Non Scaleable Content
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Investors List
Alumni Ventures
Alumni Ventures investment in Venture Round - miRecule
Alexandria Venture Investments
Alexandria Venture Investments investment in Venture Round - miRecule
(Momentum Fund) University System of Maryland
(Momentum Fund) University System of Maryland investment in Venture Round - miRecule
FSHD Society
FSHD Society investment in Venture Round - miRecule
Pathway Bioventures
Pathway Bioventures investment in Venture Round - miRecule
Boutique Venture Partners
Boutique Venture Partners investment in Venture Round - miRecule
Boutique Venture Partners
Boutique Venture Partners investment in Seed Round - miRecule
Pathway Bioventures
Pathway Bioventures investment in Seed Round - miRecule
Alumni Ventures
Alumni Ventures investment in Seed Round - miRecule
Alexandria Venture Investments
Alexandria Venture Investments investment in Seed Round - miRecule
Official Site Inspections
http://www.mirecule.com
- Host name: 104.21.67.223
- IP address: 104.21.67.223
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "miRecule"
miRecule | RNA Therapeutics
MiRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create …See details»
miRecule, Inc. | LinkedIn
We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our …See details»
miRecule - Crunchbase Company Profile & Funding
MiRecule is an early-stage biotechnology company that focuses on developing Antibody RNA Conjugate (ARC) based therapeutics.See details»
Team - miRecule
MiRecule, Inc. 704 Quince Orchard Road Gaithersburg, MD 20878. Follow; FollowSee details»
Technology Platform - miRecule
MiRecule’s ® discovery engine integrates genomic sequencing profiles and clinical outcome measures on disease progression from hundreds of patients to identify RNA therapeuticSee details»
miRecule Inc. closes $5.7 M to Create Breakthrough …
(May, 25 2021) miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by …See details»
SOLVE FSHD Invests US $1 Million in miRecule | FSHD Society
Oct 3, 2022 · miRecule, Inc. is a biotechnology company focused on advancing next-generation RNA therapeutics utilizing personalized genomic patient data to create highly tailored …See details»
miRecule Enters into Strategic Collaboration with …
Oct 4, 2022 · Under the terms of the collaboration agreement, miRecule will grant Sanofi an exclusive worldwide license to intellectual property rights to the FSHD therapy. miRecule and Sanofi will collaborate...See details»
miRecule, Inc., is developing a novel treatment for FSHD
Nov 8, 2019 · With a strong resolve to take on FSHD, miRecule raised some initial funding from family members, hired a full-time scientist dedicated to FSHD, and began work designing an RNA therapeutic targeting DUX4.See details»
miRecule Company Profile 2024: Valuation, Funding & Investors
Operator of a micro RNA-based therapeutics platform intended to treat cancer and muscular dystrophy.See details»
Anthony Saleh - Co-founder and CEO at miRecule - The Org
Currently, Saleh is the Co-founder and CEO of miRecule, Inc., a role they have held since 2018. Anthony Saleh earned a Ph.D in Biochemistry and Molecular Biology from Johns Hopkins …See details»
News Release - miRecule
Sep 29, 2022 · miRecule, Inc. is a biotechnology company focused on advancing next-generation RNA therapeutics utilizing personalized genomic patient data to create highly tailored …See details»
Gaithersburg's miRecule Inc. closes $5.7M to Create ... - BioBuzz
May 24, 2021 · miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in …See details»
Partner Spotlight: miRecule and Sanofi drive the emergence of …
Jul 27, 2023 · In 2022, Sanofi announced its partnership with miRecule, combining Sanofi’s experience and best practices with the biotech’s speed and ability to drive novel therapies …See details»
miRecule Inc. closes $5.7 M to Create Breakthrough RNA …
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, …See details»
miRecule Company Profile - Office Locations, Competitors, …
MiRecule is a biotechnology company developing microRNA-based therapeutics. It offers a miRecule genomics-based drug discovery platform that integrates genomic sequencing, …See details»
News - miRecule
May 27, 2021 · miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. …See details»
miRecule - VentureRadar
Website: http://miRecule.com Develops RNA-based therapeutics using genomic patient data for personalized treatments, focusing on diseases like cancer, muscular dystrophy, and COVID …See details»
miRecule Inc. closes $5.7 M to Create Breakthrough RNA
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, …See details»
Sanofi wagers $400M in biobucks to go after muscular dystrophy
Oct 4, 2022 · Sanofi has joined the pile-on of drug developers targeting one of the biggest unmet needs in muscular dystrophy, committing to $30 million in upfront and near-term payments for …See details»